Patents by Inventor Matthew I. Gross

Matthew I. Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arginase inhibitor combination therapies
    Patent number: 11291674
    Abstract: The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: April 5, 2022
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Amani Makkouk, Matthew I. Gross, Francesco Parlati
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20210361649
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: March 4, 2021
    Publication date: November 25, 2021
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210077510
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10940148
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10905701
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 2, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
    Publication number: 20200038398
    Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and a second anticancer agent such as osimertinib, pazopanib, navitoclax, palbociclib, or olaparib. The invention further relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and conventional radiotherapy or stereotactic body radiotherapy.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 6, 2020
    Inventors: Susan D. Bromley, Francesco Parlati, Matthew I. Gross, Keith Orford
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20190343852
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Application
    Filed: July 29, 2019
    Publication date: November 14, 2019
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10398714
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 3, 2019
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20190231776
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 1, 2019
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10258619
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors
    Patent number: 10195197
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180360860
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10143699
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 4, 2018
    Assignee: Calithera Biosciences, Inc.
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180222926
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 9, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Jr, Lene Raunkjaer PETERSEN, Francesco PARLATI, Matthew I. GROSS
  • ARGINASE INHIBITOR COMBINATION THERAPIES
    Publication number: 20180161349
    Abstract: The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
    Type: Application
    Filed: November 8, 2017
    Publication date: June 14, 2018
    Inventors: Amani MAKKOUK, Matthew I. GROSS, Francesco PARLATI
  • Combination Therapy with Glutaminase Inhibitors
    Publication number: 20180055842
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 1, 2018
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20170095473
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: October 4, 2016
    Publication date: April 6, 2017
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Compositions and Methods for Inhibiting Arginase Activity
    Publication number: 20160375044
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS
    Publication number: 20160287564
    Abstract: In some aspects, the invention relates to a method of treating cancer, a myeloproliferative disease, an immunological disease, a neurological disease, or a viral infection, comprising orally administering a compound of formula I, formula II, formula III, formula IV, formula V, and/or formula VI, wherein the compound is administered with a meal (e.g., with food as defined herein) or in fed mode.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 6, 2016
    Inventors: Matthew I. Gross, Mark K. Bennett, Christopher Molineaux
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
    Publication number: 20150258082
    Abstract: The invention relates to methods of treating cancer, myeloproliferative disorders or immunological diseases with a combination of an immunomodulatory agent and a glutaminase inhibitor. The invention further relates to methods of treating cancer, myeloproliferative disorders, or immunological diseases that are resistant to one or more immunomodulatory agents.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Francesco Parlati, Mirna L. Rodriguez, Matthew I. Gross, Terri L. Davis, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren